Cost-effectiveness of continuous subcutaneous insulin infusion versus multiple daily injections of insulin in Type 1 diabetes: A systematic review

Diabetic Medicine

Volumn 32, Issue 11, 2015, Pages 1415-1424

  Roze, S ^a   Smith Palmer, J ^b   Valentine, W ^b   de Portu, S ^c   Norgaard K ^d   Pickup, J C ^e  

^a HEVA HEOR   (France)

^b Ossian Health Economics and Communications   (Switzerland)

^c Medtronic International Sàrl ^*  (Switzerland)

^d HVIDOVRE HOSPITAL   (Denmark)

^e GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ARTICLE; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; LIFE EXPECTANCY; META ANALYSIS (TOPIC); QUALITY ADJUSTED LIFE YEAR; QUALITY CONTROL; RESOURCE MANAGEMENT; SCREENING; SYSTEMATIC REVIEW; ADVERSE EFFECTS; BLOOD; COMPARATIVE STUDY; COMPLICATION; COST BENEFIT ANALYSIS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; ECONOMICS; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HYPERGLYCEMIA;

COST-BENEFIT ANALYSIS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; EVIDENCE-BASED MEDICINE; HEALTH CARE COSTS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS; QUALITY-ADJUSTED LIFE YEARS;

EID: 84945454439     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12792     Document Type: Article

References (38)

1. Pickup JC, Keen H, Parsons JA, Alberti KGMM. Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia. BMJ 1978; 1: 204-207.
2. Pickup JC. Insulin-pump therapy for type 1 diabetes mellitus. NEJM 2012; 366: 1616-1624.
3. National Institute for Health and Clinical Excellence. Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus. NICE technology appraisal guidance 151, 2008. Available at http://www.nice.org.uk/nicemedia/pdf/ta151guidance.pdf Last accessed 11 October 2013.
4. Fox LA, Buckloh LM, Smith SD, Wysocki T, Mauras N. A randomized controlled trial of insulin pump therapy in young children with type 1 diabetes. Diabetes Care 2005; 28: 1277-1281.
5. Willi SM, Planton J, Egede L, Schwarz S. Benefits of continuous subcutaneous insulin infusion in children with type 1 diabetes. J Pediatr 2003; 143: 796-801.
6. Bode BW. Insulin pump use in type 2 diabetes. Diabet Technol Therapeut 2010; 12(Suppl 1): 17-21.
7. Reznik Y, Cohen O. Insulin pump therapy for type 2 diabetes. Use and misuse of continuous subcutaneous insulin infusion in type 2 diabetes. Diabetes Care 2013; 36(Suppl 2): 219-225.
8. Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. BMJ 2002; 324: 705.
9. Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R. Insulin pump therapy: a meta-analysis. Diabetes Care 2003; 26: 1079-1087.
10. Jeitler K, Horvath K, Berghold A, Gratzer TW, Neeser K, Pieber TR et al. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis. Diabetologia 2008; 51: 941-951.
11. Pickup JC, Sutton AJ. Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med 2008; 25: 765-774.
12. Monami M, Lamanna C, Marchionni N, Mannucci E. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 1 diabetes: a meta-analysis. Acta Diabetol 2010; 47(Suppl 1): 77-81.
13. Pickup JC. The evidence base for diabetes technology: appropriate and inappropriate meta-analysis. J Diabet Sci Technol 2013; 7: 1567-1574.
14. DeVries JH, Snoek FJ, Kostense PJ, Masurel N, Heine RJ. A randomized trial of continuous subcutaneous insulin infusion and intensive injection therapy in type 1 diabetes for patients with long-standing poor glycaemic control. Diabetes Care 2002; 25: 2074-2080.
15. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group, Nathan DM, Zinman B, Cleary PA, Backlund JY, Genuth S et al. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Arch Intern Med 2009; 169: 1307-1316.
16. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996; 313: 275-283.
17. Clegg JP, Wery E, Karamalis M, Pokorski J, Mlynarski W, Valentine WJ. Health economic analysis of continuous subcutaneous insulin infusion compared to multiple daily injections for the treatment of type 1 diabetes in Poland. Value Health 2008; 11: A336.
18. Cohen N, Minshall ME, Sharon-Nash L, Zakrzewska K, Valentine WJ, Palmer AJ. Continuous subcutaneous insulin infusion versus multiple daily injections of insulin: economic comparison in adult and adolescent type 1 diabetes mellitus in Australia. Pharmacoeconomics 2007; 25: 881-897.
19. Colquitt JL, Green C, Sidhu MK, Hartwell D, Waugh N. Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes. Health Technol Assess 2004; 8: iii, 1-171.
20. Conget Donlo I, Serrano Contreras D, Rodríguez Barrios JM, Levy Mizrahi I, Castell Abat C, Roze S. [Cost-utility analysis of insulin pumps compared to multiple daily doses of insulin in patients with type 1 diabetes mellitus in Spain]. Rev Esp Salud Publica 2006; 80: 679-695.
21. Cummins E, Royle P, Snaith A, Greene A, Robertson L, McIntyre L et al. Clinical effectiveness and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes: systematic review and economic evaluation. Health Technol Assess 2010; 14: iii-iv, xi-xvi, 1-181.
22. Nørgaard K, Sohlberg A, Goodall G. [Cost-effectiveness of continuous subcutaneous insulin infusion therapy for type 1 diabetes]. Ugeskr Laeger 2010; 172: 2020-2025.
23. Roze S, Valentine WJ, Zakrzewska KE, Palmer AJ. Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of Type 1 diabetes in the UK. Diabet Med 2005; 22: 1239-1245.
24. Scuffham P, Carr L. The cost-effectiveness of continuous subcutaneous insulin infusion compared with multiple daily injections for the management of diabetes. Diabet Med 2003; 20: 586-593.
25. St Charles M, Lynch P, Graham C, Minshall ME. A cost-effectiveness analysis of continuous subcutaneous insulin injection versus multiple daily injections in type 1 diabetes patients: a third-party US payer perspective. Value Health 2009; 12: 674-686.
26. St Charles ME, Sadri H, Minshall ME, Tunis SL. Health economic comparison between continuous subcutaneous insulin infusion and multiple daily injections of insulin for the treatment of adult type 1 diabetes in Canada. Clin Ther 2009; 31: 657-667.
27. Lynch P, Giardina S, Nicolucci A, Papo NL, Orsini Federici M, Minshall ME. Cost-effectiveness analysis of continuous subcutaneous insulin injection vs. multiple daily injections in type 1 diabetes patients: an Italian perspective. Poster presented at the 44th Annual Meeting of the European Association for the Study of Diabetes, Rome, Italy, 7-11 September 2008.
28. Shu J, Zeng LY, Mu PW, Wang MM, Zhang GC, Chen YM. Cost-effectiveness analysis on continuous subcutaneous insulin infusion and multi-point daily insulin injections in the treatment program of type 2 diabetes. Zhonghua Liu Xing Bing Xue Za Zhi 2009; 30: 73.
29. McCabe C, Claxton K, Culyer AJ. The NICE cost-effectiveness threshold: what it is and what that means. Pharmacoeconomics 2008; 26: 733-744.
30. DeVries JH, Heine RJ. Insulin pump therapy: a meta-analysis: response to Weissberg-Benchell et al. Diabetes Care 2003; 26: 2485.
31. DeVries JH. Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of Type 1 diabetes in the UK: response to Roze et al. Diabet Med 2006 23: 709; author reply 708.
32. Home PD. Cost-effectiveness of CSII. Diabet Med 2006; 23: 707; author reply 707-708.
33. Pickup JC, Kidd J, Burmiston S, Yemane N. Determinants of glycaemic control in type 1 diabetes during intensified therapy with multiple daily insulin injections or continuous subcutaneous insulin infusion: importance of blood glucose variability. Diabet Metab Res Rev 2006; 22: 232-237.
34. Retnakaran R, Hochman J, DeVries JH, Hanaire-Broutin H, Heine RJ, Melki V et al. Continuous subcutaneous insulin infusion versus multiple daily injections. The impact of baseline A1c. Diabetes Care 2004; 27: 2590-2596.
35. Pickup JC, Kidd J, Burmiston S, Yemane N. Effectiveness of continuous subcutaneous insulin infusion in hypoglycaemia-prone type 1 diabetes. Pract Diabetes Int 2005; 22: 10-14.
36. Palmer AJ, Roze S, Valentine WJ, Spinas G. The cost-effectiveness of continuous subcutaneous insulin infusion compared with multiple daily injections for the management of diabetes: response to Scuffham and Carr. Diabet Med 2004; 21: 1372.
37. Brod M, Christensen T, Thomsen TL, Bushnell DM. The impact of non-severe hypoglycaemic events on work productivity and diabetes management. Value Health 2011; 14: 665-671.
38. Nixon R, Folwell R, Pickup JC. Variations in the quality and sustainability of long-term glycaemic control with continuous subcutaneous insulin infusion. Diabet Med 2014; 31: 1174-1177.